AI medical trial: detecting thyrotoxicosis from consumer-wearable heart rate with AI (Thyroscope, Glandy HYPER)
An observational study evaluating whether the AI software device "Glandy HYPER" can detect a thyrotoxic state in hyperthyroidism (Graves' disease) using heart-rate data from commercial wearables, correlated with thyroid function tests (free T4).
Trial overview (primary data)
- StatusRecruiting
- ConditionsGraves Disease, Hyperthyroidism/Thyrotoxicosis
- InterventionsDEVICE: Heart rate-based AI software for detecting thyrotoxicosis
- SponsorTHYROSCOPE INC.
- Target enrollment15 participants
- Period2026-01-09 〜 2026-12-31
Key points
- Detects thyrotoxicosis (Graves' disease) from consumer-wearable heart rate + AI
- Evaluates the software medical device "Glandy HYPER" (observational)
- Correlates sleep heart rate with thyroid function tests (free T4)
- Device output is not disclosed to participants; standard care is unchanged
- Small early-stage study (15 participants), 2026, recruiting
Thyroscope's observational study (NCT07017907) evaluates an AI software medical device, "Glandy HYPER," that uses heart rate from a commercial wearable to detect an overactive thyroid (thyrotoxicosis).
Per the registry summary, this observational study aims to evaluate the performance of the software-based medical device "Glandy HYPER" in detecting the thyrotoxic state in patients with hyperthyroidism. The device uses heart-rate data from commercially available wearables and compares it with thyroid function test results. The study enrolls patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating it with serial free-T4 levels obtained by blood testing. Importantly, no investigational device output is disclosed to participants, and the study does not alter standard clinical care. Target enrollment 15; 2026; recruiting.
In hyperthyroidism (e.g., Graves' disease), metabolism is elevated, causing palpitations, rapid heart rate, and weight loss; worsening thyrotoxicosis strains the heart. Because heart rate can be measured continuously and easily with consumer smartwatches, combining it with AI to flag signs of a thyrotoxic state could help with deciding when to seek care or with monitoring. Note this is an early, small (15-participant) observational study.
Why it matters
Consumer wearables plus AI as "digital biomarkers" to flag disease signs is a globally watched area. As smartwatch health use spreads, such studies show how their validity is being tested (note this is an early, small study).
FAQ
What is thyrotoxicosis?
Can a smartwatch diagnose it?
Sources (primary)
Source: ClinicalTrials.gov (U.S. NIH/NLM, public domain). This site does not provide medical advice. Verify the latest and exact details with the official source. This site is not endorsed or certified by the NIH/NLM.
- ClinicalTrials.gov (study record, original)
- NCT ID: NCT07017907